A 27-year-old man with diagnosis of New Onset Refractory Status Epilepticus (NORSE) was treated with five anti-seizure drugs (ASDs) including clobazam, levetiracetam and topiramate. He received plasma exchange (PE) for presumed autoimmune etiology. Serum ASD levels were serially monitored in two sessions. Levels of clobazam, levetiracetam and topiramate were significant reduced by PE. Serum clobazam level dropped down to at least
85% and 75% of the baseline during and after the procedure respectively; levetiracetam dropped down to 83% and 83%; and topiramate dropped to 86% and 79%. The results may imply a theoretical risk of breakthrough seizure.
INTRODUCTION
Plasma exchange (PE) or plasmapheresis is a therapy involving removal of patient's plasma in exchange of exogenous fluid such as albumin. Its use in neurology is increasing as autoimmunity has been discovered to play an etiological role in many neurological diseases [1, 2] . At the same time, seizures can occur in many neuro-immunological disorders such as autoimmune encephalitis, multiple sclerosis, paraneoplastic syndrome, etc. There are concerns about whether PE would affect the serum concentration of anti-seizure drug (ASD). Clinicians may query whether patients would bare higher seizure risk around the time of PE and whether there is a need to adjust the ASD dosage for the procedure.
We present a patient with New Onset Refractory Status Epilepticus (NORSE) who was empirically treated with PE. His serum ASD levels before, during and after two of his PE sessions were recorded. To our best knowledge, it is the first report on the effect of PE on serum levels of clobazam, levetiracetam and topiramate.
A 27 year-old man presented to us for first ever generalized tonic-clonic Our patient was on five ASDs administrated at specified timings around both PE studies (table 1A) . All the ASDs had been started for at least two days before the first PE study. Majority of the ASDs were given by intravenous route.
The concomitant medication and intravenous infusion were listed out (table   1B) . His serum albumin levels were 29g/L and 43g/L before first and second PE studies respectively.
Specimen collection
Serum samples for clobazam, levetiracetam, topiramate, phenytoin and valproate assays were collected before, around the middle and half an hour after each PE study.
Drug level Assay
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The serum levels of clobazam, levetiracetam and topiramate were measured by Nation Medical Services Labs (PA, USA) using liquid chromatography tandem-mass spectrometry. The serum level assays of phenytoin and valproate were done by the biochemistry laboratory of our institution. Serum phenytoin level was measured by competitive immunoassay (VITROS PHYT Slide, manufactured by Ortho-Clinical Diagnostics, Rochester, NY, USA).
Serum valproate was measured by competitive immunoassay (VITROS 5600
Integrated System, manufactured by Ortho-Clinical Diagnostics, Rochester, NY, USA). Total, instead of free drug, levels were measured.
RESULTS
Changes in the plasma level of the five ASDs around the two PE studies are shown (table 1C ). Patient did have convulsion during and immediately after these two PE sessions. The serum levels of clobazam, levetiracetam and topiramate dropped appreciably during the course of PE. The drops in ASD level during and after PE varies between 60% to 86% compared to the pre-PE levels as baseline (figure 1).
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The changes in serum phenytoin could not be assessed as the serum levels of the drug remained low so that they were unable to be reliably quantified by our laboratory. This was probably because our patient was a fast metabolizer of phenytoin. Case of persistent low serum phenytoin level due to hypermetabolism has been described [3] .
The serum valproate levels showed a reduction in the first PE study. However, in the second PE study, there was a rise in serum valproate level. We consider the result was not reliable and could not reflect the effect of PE as there was an intravenous bolus dose of 600mg valproate at around the commencement of the PE process (table 1B) . The valproate levels during and after PE may be affected by the injection directly. For drug factor, the higher protein binding tendency of the drug molecule, the greater portion of drug remains in blood and thus can be removed by PE [6] .
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This is in contrast to other extracorpereal treatments such as haemofiltration and haemodialysis in which drugs with more protein bound are theoretically less likely to pass through the semi-permeable membrane and get removed [7] .
Also, the lower the volume of distribution of a drug means a larger proportion of it is within the intravascular compartment [6] . As a result, larger amount of the drug is removed by PE. For example, theophylline, a drug with high plasm protein binding and low volume of distribution, has been reported to be effectively removed by PE [8].
Timing of dosing also plays a role. Intravenous medication dosed shortly before commencement of PE means the plasma concentration of drug is highest because the drug has yet to distribute to other body compartments.
Thus, the higher the concentration of the drug at the start of the PE means a larger portion of it ended up being removed. Practically, it may be advisable to suggest a longer time gap between drug administration and PE in order to minimize medication removal by plasma exchange.
The drops in ASD plasma levels during and after PE may lead to the concern of the patient's vulnerability to seizure and hence the necessity to increase the A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T Table 1C legend Changes of serum ASD levels around the two PE studies.
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Highlights  Plasmapheresis is shown to cause significant decrease in serum levels of clobazam, levetiracetam and topiramate.  There is a theoretical risk of seizure in the period around plasmapheresis due to fluctuation in the serum level of the anticonvulsant.  Plasmapheresis may have a role in management of anticonvulsant toxicity.
